Cyprotex PLC Launch of new chemPK workflow solution
July 14 2015 - 2:00AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
14 July 2015
Cyprotex launches new chemPK(TM) workflow solution to predict
human pharmacokinetics directly from chemical structure
14th July, 2015;
Cyprotex PLC (AIM:CRX), a specialist Contract Research
Organisation (CRO), announced today the launch of its new
predictive modelling solution, chemPK(TM) , which predicts human
pharmacokinetics directly from chemical structure. Pharmacokinetics
is defined as the study of the concentration of drug in the body
over time, and is based on the absorption, distribution, metabolism
and excretion of a drug.
Our new chemPK(TM) solution has been developed by Cyprotex's
Scientific Computing Team using PBPK (physiologically based
pharmacokinetic) predictive modelling. Cyprotex have considerable
expertise in this technique, having previously developed and
launched the proprietary modelling software, Cloe(R) PK and Cloe(R)
HIA. chemPK(TM) is a virtual screening tool meaning that it can be
employed before chemical synthesis of a molecule and does not
require any data inputs. This provides significant cost benefits
and can be used as an early stage filter for directing chemistry
and prioritising in vitro screening taking account of the predicted
human pharmacokinetics.
chemPK(TM) is unique in that the model has been optimised
directly on human clinical data, and so provides a more robust
approach as compared to alternative models that use QSAR
(quantitative structure activity relationship)-based methods for
predicting their input parameters. chemPK(TM) is implemented as a
collection of nodes for the widely used KNIME workflow management
platform, enabling its use in either desktop or server
environments, and facilitating its interaction with many other
cheminformatics, analytics and modelling tools.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments:
'Our new chemPK(TM) solution provides significant advantages over
existing products in the market. It will provide our customers with
an insight into the expected exposure of a molecule in the human
body at an early stage enabling them to only synthesise compounds
with the best chance of success.'
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1000 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. The Company's core capabilities include high quality in
vitro ADME screening services, mechanistic toxicology and high
content toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, predictive modelling
using PBPK, including Cloe(R) PK for in vivo PK prediction, and a
range of skin, ocular and endocrine disruption services. For more
information, see www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRARJMTTMBBBBTA
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024